RNXT

RenovoRx Inc

May 15 • 04:00PM ET

0.8200

-0.0350 -4.09 %

Healthcare • Biotechnology • USA • Nano • NASD

May 14, 6:15 PMRenovoRx posts Q1 2026 results with EPS -$0.09 missing estimates and revenue $563,000 beating expectations

Peers: PSTV IMNN BLRX PRQR TNXP

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	4.22%	Shs Outstand	45.05M	Perf Week	-5.05%
Market Cap	36.94M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	4.05%	Shs Float	43.50M	Perf Month	-18.00%
Enterprise Value	24.77M	PEG	-	EPS next Q	-0.07	Inst Own	18.82%	Short Float	1.16%	Perf Quarter	-12.14%
Income	-12.27M	P/S	24.79	EPS this Y	10.16%	Inst Trans	-3.15%	Short Ratio	1.49	Perf Half Y	-18.00%
Sales	1.49M	P/B	3.28	EPS next Y	53.04%	ROA	-81.85%	Short Interest	0.51M	Perf YTD	-2.39%
Book/sh	0.25	P/C	2.99	EPS next 5Y	-	ROE	-100.47%	52W High	1.45 -43.45%	Perf Year	-26.13%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	33.86% 6.34%	ROIC	-108.16%	52W Low	0.70 17.04%	Perf 3Y	-63.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	78.71%	Volatility	6.52% 6.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	16.62	EPS Y/Y TTM	16.12%	Oper. Margin	-864.27%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.95	Sales Y/Y TTM	520.42%	Profit Margin	-823.98%	RSI (14)	37.69	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.15	EPS Q/Q	-20.10%	SMA20	-6.96%	Beta	0.99	Target Price	6.88
Payout	-	Debt/Eq	0.02	Sales Q/Q	185.79%	SMA50	-12.52%	Rel Volume	1.90	Prev Close	0.86
Employees	17	LT Debt/Eq	0.01	Earnings	May 14 AMC	SMA200	-18.57%	Avg Volume	340.37K	Price	0.82
IPO	Aug 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-12.50% 19.91%	Trades		Volume	647,593	Change	-4.09%

May-15-26 01:01AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion (GuruFocus.com)
May-14-26 04:05PM	RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter (GlobeNewswire)
May-13-26 09:20AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-29-26 08:30AM	RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET (GlobeNewswire)
Apr-23-26 08:30AM	RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire) -5.09%
08:30AM	Loading…
Apr-14-26 08:30AM	Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting (GlobeNewswire)
Apr-08-26 08:30AM	RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum (GlobeNewswire)
Apr-01-26 02:20PM	RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (GlobeNewswire)
Mar-30-26 11:01PM	RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -5.31% -5.61%
04:05PM	RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-26 09:19AM	Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result (GuruFocus.com)
Mar-26-26 08:30AM	RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment (GlobeNewswire) +5.45%
Mar-23-26 08:30AM	RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement (GlobeNewswire) +11.00%
Mar-20-26 08:30AM	RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET (GlobeNewswire)
Mar-18-26 08:35AM	RenovoRx Announces $10 Million at Market Private Placement (GlobeNewswire) +6.59%
05:35PM	Loading…
Mar-03-26 05:35PM	Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.51%
Feb-28-26 09:01AM	RenovoRx advances RenovoCath adoption at U.S. cancer centers (TipRanks)
Feb-27-26 08:30AM	RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum (GlobeNewswire)
Feb-26-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting (GlobeNewswire)
Feb-10-26 08:30AM	RenovoRx Establishes RenovoCath Medical Advisory Board (GlobeNewswire)
Feb-05-26 08:30AM	RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer (GlobeNewswire)
Feb-04-26 08:30AM	RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting (GlobeNewswire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) +8.33%
Jan-28-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting (GlobeNewswire)
Jan-20-26 08:30AM	RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center (GlobeNewswire)
Jan-14-26 08:30AM	RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 (GlobeNewswire)
Jan-08-26 08:30AM	RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 (GlobeNewswire) +13.86%
Dec-11-25 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 (GlobeNewswire)
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-01-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th (GlobeNewswire) -6.59%
08:30AM	Loading…
Nov-19-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th (GlobeNewswire) -6.38%
Nov-14-25 12:04AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Call Highlights: Strong Commercial Momentum and Strategic ... (GuruFocus.com) -23.03%
Nov-13-25 05:30PM	RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update (GlobeNewswire)
Nov-12-25 07:36AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.54%
Nov-06-25 08:30AM	RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD (GlobeNewswire) -6.23%
Nov-04-25 08:30AM	RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th (GlobeNewswire) -6.42%
Oct-27-25 08:30AM	RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET (GlobeNewswire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-09-25 08:30AM	RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baere, MD, PhD (GlobeNewswire) -7.44%
Sep-25-25 08:30AM	RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites (GlobeNewswire)
Sep-11-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th (GlobeNewswire) +5.98%
Aug-20-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025 (Business Wire) -5.58%
Aug-15-25 03:24AM	RenovoRx Inc (RNXT) Q2 2025 Earnings Call Highlights: Strong Market Demand and Strategic Trials ... (GuruFocus.com) -22.94%
Aug-14-25 05:20PM	RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review (Business Wire)
Aug-06-25 08:30AM	RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire (GlobeNewswire)
Jul-28-25 08:30AM	RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath Device to Solid Tumors (Business Wire)
Jul-14-25 08:30AM	RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET (Business Wire) +8.95%
Jun-05-25 11:00PM	RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results (Insider Monkey)
May-16-25 09:42AM	Q1 2025 RenovoRx Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
03:15AM	RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ... (GuruFocus.com)
May-15-25 07:30PM	RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.71%
04:05PM	RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-14-25 08:30AM	RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st (Business Wire)
May-06-25 08:30AM	U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP) Therapy Platform (Business Wire)
May-01-25 08:30AM	RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET (Business Wire)
Apr-29-25 08:30AM	Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRxs Ongoing Phase III TIGeR-PaC Clinical Trial (Business Wire)
Apr-16-25 08:30AM	RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community (Business Wire) +14.44%
Apr-04-25 08:30AM	RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th (Business Wire)
Apr-01-25 08:30AM	RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire)
Mar-28-25 08:00AM	RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting (Business Wire)
Mar-26-25 08:00AM	RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting (Business Wire)
Mar-20-25 08:00AM	RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET (Business Wire)
Mar-19-25 08:00AM	RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 (Business Wire)
Feb-26-25 08:00AM	RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders (Business Wire)
Feb-13-25 08:00AM	RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery (Business Wire) -11.21%
Feb-11-25 07:00AM	RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
Feb-07-25 03:11AM	RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement (GuruFocus.com) -20.55%
Feb-06-25 08:49PM	RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
04:05PM	RenovoRx Announces Proposed Public Offering (Business Wire)
Jan-27-25 12:48PM	ASCO GI: RenovoRXs TAMP system reduces side effects in pancreatic cancer (Clinical Trials Arena)
08:00AM	RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 (Business Wire)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-08-25 08:00AM	RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 (Business Wire)
Dec-30-24 08:00AM	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform (Business Wire) +6.92%
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-11-24 08:00AM	RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-10-24 08:00AM	RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET (GlobeNewswire)
Dec-06-24 05:01AM	RenovoRx begins commercialisation of RenovoCath device (Medical Device Network)
Dec-05-24 08:00AM	RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System (GlobeNewswire) +15.97%
Nov-20-24 08:45AM	Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire) +7.21%
Nov-14-24 08:00AM	RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Sep-25-24 08:30AM	RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians (GlobeNewswire)
Sep-19-24 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
Aug-27-24 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York (GlobeNewswire)
Aug-14-24 12:13PM	RenovoRx continues drug-device combo Phase III trial in pancreatic cancer (Medical Device Network)
08:30AM	RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Aug-13-24 10:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 (InvestorPlace)
Jul-31-24 08:30AM	RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) -6.98%
Jul-08-24 08:30AM	RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) +6.61%
Jun-26-24 08:30AM	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-30-24 08:30AM	RenovoRx CEO Issues Update Letter to Shareholders (Business Wire)
May-21-24 09:00AM	Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRxs TAMP Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery (Business Wire)
May-14-24 09:00AM	RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 (Business Wire)
May-13-24 09:53AM	RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024 (InvestorPlace)
May-02-24 09:00AM	RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 (Business Wire)
Apr-18-24 08:30AM	RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire)
Apr-16-24 08:30AM	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

FounderDr. Ramtin Agah M.D.

CEOMr. Shaun R. Bagai

CGMAMr. Ronald B. Kocak C.P.A.

CFO & Principal Accounting OfficerMr. Mark Voll

Vice President of Operations and R&DMr. Robert Strasser

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agah Ramtin	Chief Medical Officer	Jan 21 '26	Buy	1.00	10,000	9,975	798,460	Jan 22 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 31 '25	Buy	0.86	9,795	8,424	788,460	Jan 05 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 30 '25	Buy	0.83	205	169	778,665	Jan 02 05:00 PM
Bagai Shaun	Chief Executive Officer	Dec 18 '25	Buy	0.90	5,000	4,506	340,040	Dec 22 07:00 AM
Bagai Shaun	Chief Executive Officer	Dec 17 '25	Buy	0.85	5,000	4,262	335,040	Dec 19 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 16 '25	Buy	0.85	12,000	10,200	778,460	Dec 17 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 05 '25	Buy	0.96	10,000	9,600	766,460	Dec 08 07:00 AM
Agah Ramtin	Chief Medical Officer	Nov 24 '25	Buy	0.80	12,000	9,600	756,460	Nov 24 06:00 PM
Agah Ramtin	Chief Medical Officer	Nov 21 '25	Buy	0.80	10,000	8,000	744,460	Nov 24 06:00 PM
Bagai Shaun	Chief Executive Officer	Aug 22 '25	Buy	0.95	5,000	4,748	325,040	Aug 26 06:10 AM
Bagai Shaun	Chief Executive Officer	Aug 25 '25	Buy	0.91	5,000	4,549	330,040	Aug 26 06:10 AM
Agah Ramtin	Chief Medical Officer	Jun 05 '25	Buy	1.40	21,000	29,400	734,460	Jun 09 06:03 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNXT

RenovoRx Inc

Upgrade your Finviz experience